A Phase I Study of BKM120 and Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Latest Information Update: 04 Jul 2022
At a glance
- Drugs Buparlisib (Primary) ; Rituximab
- Indications B-cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 27 Jun 2022 Status changed from active, no longer recruiting to completed.
- 29 Sep 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 25 Mar 2020 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.